Spark Therapeutics (NASDAQ:ONCE) has been given a $105.00 price objective by research analysts at Cantor Fitzgerald in a note issued to investors on Monday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 43.09% from the company’s previous close.
The analysts wrote, “Update at ASH in four Hemophilia A patients raises new questions on variability of factor VIII expression levels associated with SPK-8011’s treatment.””
ONCE has been the subject of a number of other reports. Cowen restated a “buy” rating and issued a $95.00 price objective on shares of Spark Therapeutics in a report on Tuesday, October 10th. Raymond James Financial restated a “buy” rating on shares of Spark Therapeutics in a research note on Thursday. Barclays raised their price objective on shares of Spark Therapeutics from $104.00 to $107.00 and gave the stock an “overweight” rating in a report on Friday, October 13th. Chardan Capital reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Spark Therapeutics in a report on Friday, October 13th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $101.00 price target (up from $89.00) on shares of Spark Therapeutics in a report on Friday, October 13th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and eighteen have assigned a buy rating to the company’s stock. Spark Therapeutics has an average rating of “Buy” and an average target price of $90.97.
Shares of Spark Therapeutics (NASDAQ:ONCE) traded up $2.82 during trading hours on Monday, hitting $73.38. 669,500 shares of the stock traded hands, compared to its average volume of 398,833. Spark Therapeutics has a 52 week low of $47.03 and a 52 week high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.79) by ($0.11). The company had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The firm’s quarterly revenue was up 45.8% on a year-over-year basis. During the same quarter last year, the company posted ($1.07) earnings per share. research analysts predict that Spark Therapeutics will post -7.6 EPS for the current fiscal year.
In other Spark Therapeutics news, insider Katherine A. High sold 5,000 shares of the business’s stock in a transaction dated Tuesday, September 26th. The shares were sold at an average price of $86.16, for a total value of $430,800.00. Following the transaction, the insider now owns 215,000 shares in the company, valued at $18,524,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Stephen W. Webster sold 10,000 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $70.14, for a total transaction of $701,400.00. Following the completion of the transaction, the chief financial officer now owns 12,500 shares in the company, valued at approximately $876,750. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,074,809 shares of company stock worth $90,304,385. 7.30% of the stock is owned by corporate insiders.
Several hedge funds have recently added to or reduced their stakes in ONCE. JPMorgan Chase & Co. increased its stake in shares of Spark Therapeutics by 15.0% in the third quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock worth $164,986,000 after purchasing an additional 241,016 shares in the last quarter. BlackRock Inc. increased its stake in Spark Therapeutics by 11.6% in the second quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock valued at $122,689,000 after purchasing an additional 213,520 shares during the last quarter. TIAA CREF Investment Management LLC increased its stake in Spark Therapeutics by 20.3% in the second quarter. TIAA CREF Investment Management LLC now owns 62,480 shares of the biotechnology company’s stock valued at $3,733,000 after purchasing an additional 10,544 shares during the last quarter. Balyasny Asset Management LLC increased its stake in Spark Therapeutics by 104.8% in the second quarter. Balyasny Asset Management LLC now owns 59,400 shares of the biotechnology company’s stock valued at $3,549,000 after purchasing an additional 30,400 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. purchased a new position in Spark Therapeutics in the third quarter valued at approximately $5,286,000. Hedge funds and other institutional investors own 94.94% of the company’s stock.
WARNING: “Spark Therapeutics (ONCE) PT Set at $105.00 by Cantor Fitzgerald” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/11/spark-therapeutics-once-pt-set-at-105-00-by-cantor-fitzgerald.html.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.